Search peptides, terms, sources/

Immune & Infectious Disease Research

Immune and infectious disease research covers peptides studied for effects on the immune system and on infection outcomes, including sepsis and hepatitis B. The evidence ranges from laboratory work to meta-analyses of randomised trials. Results are mixed: one pooled analysis lost statistical significance when limited to higher-quality trials. A peptide's presence here is not a confirmed treatment effect.

Which peptides have been studied in immune & infectious disease research?

  • KPVLys-Pro-Val

    Three-amino-acid fragment of alpha-MSH, studied in cell and mouse models of inflammation. Not licensed in the UK. No human trial of KPV was found.

    Immune and longevityAnimal studiesEvidence reviewed
    PreliminaryNot licensed in the UK
  • Thymosin Alpha-1Thymalfasin

    Immune-regulating peptide studied in sepsis, pancreatitis and hepatitis B. Not licensed in the UK; meta-analyses show mixed results.

    Immune and longevityHuman trialsEvidence reviewed
    ModerateNot licensed in the UK

View in the full index

Best recorded finding for each peptide in this area

The best recorded finding for each peptide in this area. Each row grades one finding, not the peptide or the medicine.
PeptideUK statusFindingStudy typeEvidence grade
KPVNot licensed in the UKPepT1 uptake, cells and miceAnimalPreliminary
Thymosin Alpha-1Not licensed in the UKSepsis 28-day mortalityHuman trialModerate

"Immune & Infectious Disease Research" groups peptides studied for immunomodulatory effects and outcomes in infectious or critical-illness contexts, including sepsis, chronic viral hepatitis and immune-marker changes during recovery from acute illness. Evidence in this category spans mechanistic dendritic-cell and Toll-like-receptor research through to systematic reviews and meta-analyses of randomised controlled trials, with reported outcomes that are mixed rather than uniformly positive, including a primary meta-analysis whose result was no longer statistically significant once restricted to higher-quality trial subsets. Inclusion in this category reflects a substantial published immunology and infectious-disease research literature, not a confirmed treatment effect for any condition.

6 sources in the library relate to this area. See them.

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.